Irwin A. Braude, D.Sc., has over 20 years of experience in drug discovery and development.
He began his career as a Senior Scientist and head of the Lymphokine Research Group at the Revlon Health Care Group. While there, Dr. Braude's laboratory became the first group to develop methods for the production, purification, and sequencing of human gamma interferon. Furthermore, in collaboration with the National Cancer Institute and M.D. Anderson Tumor Clinic, they became the first group in the world to conduct clinical trials with human gamma interferon.
Dr. Braude also took a sabbatical at the National Institutes of Health, and served as a Senior Scientist in the Tumor Immunology Department at Bristol-Myers Corporation.
While at Cetus Corporation, Dr. Braude held the joint positions of Senior Scientist and Project Manager for the Autoimmune, Inflammation and Transplantation Group. His responsibilities also included supervising the company's biological screening effort and development of the company's lead immunosuppressive compound.
Dr. Braude has authored over 20 scientific publications and holds nine USA patents, with several filings pending.
Dr. Braude earned a B.A. in Political Science from Oakland University, a M.S. in Microbiology from Michigan State University, and a D.Sc. in Virology from the Catholic University of Leuven. He also served as a Postdoctoral Fellow at the Memorial Sloan-Kettering Cancer Center.